Federal Register Notice: FDA is canceling the 2/20 Pulmonary-Allergy Drugs Advisory Committee meeting scheduled to discuss a Jerini NDA for icatibant solution for injection (Firazyr). The product is proposed for treating attacks of hereditary angioedema. FDA notified the company in January that the meeting was no longer necessary and that the agency would continue with priority review of the product. Contact Teresa A. Watkins, (301) 827-7001. To view this notice, click here.